← All sarcoma trials
Recruiting nowN/AAges 18 Years and up

Intravital Microscopy in Human Solid Tumors

Sponsor: Mayo Clinic · NCT03823144 on ClinicalTrials.gov ↗

Conditions studied

Solid Tumor, AdultClinical Stage IV Gastric Cancer AJCC v8Malignant Solid NeoplasmMetastatic Colorectal CarcinomaMetastatic Gastric CarcinomaMetastatic Primary Malignant Brain NeoplasmMetastatic SarcomaPostneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8Resectable Colorectal CarcinomaResectable Liver and Intrahepatic Bile Duct CarcinomaResectable Pancreatic CarcinomaResectable SarcomaStage IV Colorectal Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Brain NeoplasmMetastatic Breast CarcinomaMetastatic Liver CarcinomaMetastatic Pancreatic CarcinomaResectable Brain NeoplasmResectable Breast CarcinomaResectable Gastric CarcinomaStage IV Hepatocellular Carcinoma AJCC v8Stage IV Pancreatic Cancer AJCC v8

What it tests

  • Diagnostic Microscopydevice
  • Fluorescein Sodium Injectiondrug

Where it's running1 site

  • Mayo Clinic Florida

    Jacksonville, Florida 32224

    Recruiting now
    • Emmanuel M Gabriel, M.D., Ph. D.(contact)904-953-2523[email protected]
    • Emmanuel M Gabriel, M.D., Ph. D.(principal investigator)
    • Michael B Wallace, M.D.(sub investigator)
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Age ≥ 18 years of age
* Eastern Cooperative Oncology Group (ECOG)Performance Status of ≤ 2
* Measurable tumor by direct visualization requiring surgical resection in the operating room (OR)
* Tumor types of origin include gastric, pancreatic, hepatobiliary, colorectal, sarcoma, brain, or breast cancer that may involve the axillary lymph nodes cancers. Tumors may be primary or metastatic
* Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent
* Subject must have a skin prick test pre-operatively (at the time of the preoperative visit and after signed informed consent for entry into this clinical trial is given) to determine any sensitivity to fluorescein

Exclusion Criteria:

* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
* Renal dysfunction as defined as a glomerular filtration rate (GFR) \< 45
* Liver dysfunction as defined by Child-Pugh score \> 5, or liver function test (LFT)'s 1.5 x above normal range
* Any known allergy or prior reaction to fluorescein or a positive skin prick test to fluorescein
* Pregnant or nursing female subjects, determined preoperatively with a urine pregnancy test
* Unwilling or unable to follow protocol requirements
* Any condition which in the investigators' opinion deems the patient unsuitable (e.g., abnormal electrocardiography \[EKG\], including T wave inversion, elevated T waves, prolonged QRS interval, or conduction blocks) or that requires further work-up (including cardiac echo or stress test)
* Any condition that excludes surgical resection as the standard of care for the patient

Updated 2026-06-02 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.